Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients

Bone Marrow Transplantation

Volumn 27, Issue 4, 2001, Pages 349-354

  Kroger N ^a   Zabelina, T ^b   Kruger W ^a   Renges, H ^a   Stute, N ^a   Kabisch, H ^a   Jaburg, N ^a   Loliger C ^a   Krull A ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Pavlow University   (Russian Federation)

Author keywords

Anti thymocyte globulin; Busulfan; Chronic myeloid leukemia; Total body irradiation; Unrelated bone marrow transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GLOBULIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MESNA; METHOTREXATE; METRONIDAZOLE; OFLOXACIN; PENTAMIDINE; PHENYTOIN; PROSTAGLANDIN E1; PROSTAVASIN; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGE; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE SEVERITY; DONOR; DRUG EFFECT; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOCYTE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; RELATIVE; SEIZURE; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL TIME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 17744368455     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702802     Document Type: Article

References (26)

1. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: A comparison of complications in the first 2 years
2. Unrelated donor marrow transplantation for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program
3. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
4. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
5. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
6. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: A randomized trial of busulfan-cytoxan versus cytoxan-Total-body irradiation as preparative regimen: A report from the Marrow Graft
7. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide
8. Graft failure after bone marrow transplantation from unrelated donors using busulfan and cyclophosphamide for conditioning
9. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy
10. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen. Low incidence of failed engraftment and severe acute GVHD
11. Busulfan/cyclosphosphamide in volunteers unrelated donor (VUD) BMT: Excellent feasibility and low incidence of treatment-related toxicity
12. 1994 Consensus Conference on acute GVHD-grading
13. Regimen related toxicity in patients undergoing bone marrow transplantation
14. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
15. The use of unrelated bone marrow donors in the treatment of chronic myelogenous leukemia: Experience of four centers
16. Marrow transplantation for acute non-lymphomic leukemia after treatment with busulfan and cyclosphosphamide
17. Bone marrow transplantation for leukemia following new busulfan and cyclophosphamide regime
18. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclosphosphamide for preparative regimen
19. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantion Group
20. I.V. busulfan, cytoxan and allogeneic hematopoietic stem cell transplantation for advanced hematological malignancies
21. Bone marrow transplantation for chronic myeloid leukemia: Long terms results
22. European results of matched unrelated bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching
23. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: The effect of leukemia burden, donor HLA-matching and marrow cell dose
24. Anti-human T-lymphocyte globulin (ATG) as part of the conditioning regimen in unrelated bone marrow transplantation of patients with CML in chronic or accelerated phase
25. Bone marrow transplantation from mismatched unrelated donors
26. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow